These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 19188675)
1. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. Brandes AA; Tosoni A; Franceschi E; Sotti G; Frezza G; Amistà P; Morandi L; Spagnolli F; Ermani M J Clin Oncol; 2009 Mar; 27(8):1275-9. PubMed ID: 19188675 [TBL] [Abstract][Full Text] [Related]
2. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844 [TBL] [Abstract][Full Text] [Related]
3. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829 [TBL] [Abstract][Full Text] [Related]
4. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820 [TBL] [Abstract][Full Text] [Related]
5. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
6. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel. Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244 [TBL] [Abstract][Full Text] [Related]
7. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W; Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102 [TBL] [Abstract][Full Text] [Related]
8. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280 [TBL] [Abstract][Full Text] [Related]
9. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial. Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R; Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067 [TBL] [Abstract][Full Text] [Related]
10. FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status. Niyazi M; Schnell O; Suchorska B; Schwarz SB; Ganswindt U; Geisler J; Bartenstein P; Kreth FW; Tonn JC; Eigenbrod S; Belka C; la Fougère C Radiother Oncol; 2012 Jul; 104(1):78-82. PubMed ID: 22673727 [TBL] [Abstract][Full Text] [Related]
11. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. Melguizo C; Prados J; González B; Ortiz R; Concha A; Alvarez PJ; Madeddu R; Perazzoli G; Oliver JA; López R; Rodríguez-Serrano F; Aránega A J Transl Med; 2012 Dec; 10():250. PubMed ID: 23245659 [TBL] [Abstract][Full Text] [Related]
12. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840 [TBL] [Abstract][Full Text] [Related]
13. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461 [TBL] [Abstract][Full Text] [Related]
14. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. Franceschi E; Depenni R; Paccapelo A; Ermani M; Faedi M; Sturiale C; Michiara M; Servadei F; Pavesi G; Urbini B; Pisanello A; Crisi G; Cavallo MA; Dazzi C; Biasini C; Bertolini F; Mucciarini C; Pasini G; Baruzzi A; Brandes AA; J Neurooncol; 2016 May; 128(1):157-162. PubMed ID: 26943851 [TBL] [Abstract][Full Text] [Related]
15. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients. McDonald KL; Rapkins RW; Olivier J; Zhao L; Nozue K; Lu D; Tiwari S; Kuroiwa-Trzmielina J; Brewer J; Wheeler HR; Hitchins MP Eur J Cancer; 2013 Jan; 49(2):360-8. PubMed ID: 22975219 [TBL] [Abstract][Full Text] [Related]
16. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Brandes AA; Franceschi E; Tosoni A; Bartolini S; Bacci A; Agati R; Ghimenton C; Turazzi S; Talacchi A; Skrap M; Marucci G; Volpin L; Morandi L; Pizzolitto S; Gardiman M; Andreoli A; Calbucci F; Ermani M Neuro Oncol; 2010 Mar; 12(3):283-8. PubMed ID: 20167816 [TBL] [Abstract][Full Text] [Related]
17. Treatment considerations for MGMT-unmethylated glioblastoma. Taylor JW; Schiff D Curr Neurol Neurosci Rep; 2015 Jan; 15(1):507. PubMed ID: 25394859 [TBL] [Abstract][Full Text] [Related]
18. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Li H; Li J; Cheng G; Zhang J; Li X Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705 [TBL] [Abstract][Full Text] [Related]
19. Glioblastoma Recurrence and the Role of O Storey K; Leder K; Hawkins-Daarud A; Swanson K; Ahmed AU; Rockne RC; Foo J JCO Clin Cancer Inform; 2019 Feb; 3():1-12. PubMed ID: 30758983 [TBL] [Abstract][Full Text] [Related]